Hardman Research

Hardman & Co

Oxford BioMedica plc New era for cell and gene therapies

Oxford Biomedica plc (LON:OXB) is a specialist advanced therapy viral-vector biopharmaceutical company. It offers vector manufacturing and development services, whilst retaining proprietary drug candidates. OXB will also receive royalties on

Hardman & Co

Diurnal Group Plc Ready to press the button

Diurnal Group Plc (LON:DNL) is a clinical stage specialty pharmaceutical company focused on diseases of the endocrine system. Its two lead candidates are targeted at rare diseases with unmet medical

Hardman & Co

1pm plc Financing powerhouse: A lunchtime treat

1pm Plc (LON:OPM) offers a unique exposure to the attractive UK, non-bank, SME financing market. We believe it can deliver superior growth from: (i) focussed business units delivering high service

Hardman & Co

PPHE Hotel Group Ltd Strong results spark upgrades

PPHE Hotel Group Ltd (LON:PPH) reported interim results which were higher than our expectations and we are modestly increasing our forecasts for this year and next. Current profitability is constrained

Hardman & Co

ValiRx Plc GeneICE and VAL101 progress

ValiRx Plc (LON:VAL) is a clinical-stage biopharmaceutical company focused on the development of therapeutics for the treatment of cancer, associated biomarkers and companion diagnostics. The company’s two leading assets are

Hardman & Co

Sinclair Pharma Plc A Prominsing Start in the US

In 2016 Sinclair Pharma Plc (LON:SPH) was transformed into a streamlined, pure-play aesthetics company with a concentrated, highly competitive, portfolio of differentiated injectable products. Effective, longer-lasting, natural looking, minimally invasive

Hardman & Co

Evgen Pharma Plc Making clinical progress

Evgen Pharma Plc (LON:EVG) is a virtual pharmaceutical company focused on the development of a synthetic version of a natural product, sulforaphane, which is known to modulate key signalling pathways